Literature DB >> 20473944

Lymphotoxin-β receptor activation by lymphotoxin-α(1)β(2) and LIGHT promotes tumor growth in an NFκB-dependent manner.

Barbara Daller1, Werner Müsch, Johann Röhrl, Alexei V Tumanov, Sergei A Nedospasov, Daniela N Männel, Wulf Schneider-Brachert, Thomas Hehlgans.   

Abstract

Lymphotoxin beta receptor (LTβR) activation on mouse fibrosarcoma cells (BFS-1) results in enhanced solid tumor growth paralleled by increased angiogenesis induced by the expression of pro-angiogenic CXCL2. In our study, we demonstrate that both functional ligands of the LTβR, namely LTα(1) β(2) and LIGHT, are involved in the activation of LTβR in solid fibrosarcomas. To identify whether the lymphocyte population is involved in the activation of LTβR in these fibrosarcoma tumors, we used conditional LTβ-deficient mice that specifically lack LTβ expression either on T cells (T-LTβ(-/-)) or on B cells (B-LTβ(-/-)). Solid tumor growth was reduced in both mouse strains when compared to tumor growth in wild-type mice, indicating the participation of both T and B host lymphocytes in the activation of LTβR in these tumors. Tumor growth was also reduced in LIGHT-deficient mice, suggesting a contribution of this ligand to the activation of LTβR in BFS-1 fibrosarcomas. LTβR signaling can involve IκBα and/or NFκB-inducing kinase (NIK) for subsequent NFκB activation in different types of cells. Expression of a dominant negative form of IκBα or of a dominant negative mutant of NIK resulted in decreased activation of NFκB signaling and reduced expression of pro-angiogenic CXCL2 in vitro. Moreover, expression of dominant negative form of NIK or an IκBα repressor in these fibrosarcoma cells resulted in reduced solid tumor growth in vivo, suggesting that both IκBα and NIK are involved in pro-angiogenic signaling after LTβR activation. Our data support the idea that the ablation of LTβR signaling should be considered for cancer treatment.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20473944     DOI: 10.1002/ijc.25456

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Lymphotoxin β receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of NF-κB activation.

Authors:  Xiaolin Hu; Mary A Zimmerman; Kankana Bardhan; Dafeng Yang; Jennifer L Waller; Georgia B Liles; Jeffrey R Lee; Raphael Pollock; Dina Lev; Carl F Ware; Ellen Garber; Veronique Bailly; Jeffrey L Browning; Kebin Liu
Journal:  Carcinogenesis       Date:  2013-01-24       Impact factor: 4.944

2.  Clinical significance of serum expression of GROβ in esophageal squamous cell carcinoma.

Authors:  Qiao-Mei Dong; Jin-Qiang Zhang; Qian Li; Jacqueline C Bracher; Denver T Hendricks; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2011-06-07       Impact factor: 5.742

3.  Antiproliferative and proapoptotic effects of a pyrrole containing arylthioindole in human Jurkat leukemia cell line and multidrug-resistant Jurkat/A4 cells.

Authors:  Alex A Philchenkov; Michael P Zavelevich; Volodymyr P Tryndyak; Ludmila M Kuiava; Dmitry Yu Blokhin; Koh Miura; Romano Silvestri; Igor P Pogribny
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

4.  Clinical significance of serum expression of GROβ in hepatocellular carcinoma.

Authors:  YueGuo Li; YuFang Wang; Peng Zhang
Journal:  Tumour Biol       Date:  2015-03-24

5.  Positive association between lymphotoxin-alpha variation rs909253 and cancer risk: a meta-analysis based on 36 case-control studies.

Authors:  Xi Yu; Yi Huang; Changhong Li; Hailian Yang; Caide Lu; Shiwei Duan
Journal:  Tumour Biol       Date:  2013-10-18

6.  Elevated NIBP/TRAPPC9 mediates tumorigenesis of cancer cells through NFκB signaling.

Authors:  Yonggang Zhang; Shu Liu; Hong Wang; Wensheng Yang; Fang Li; Fan Yang; Daohai Yu; Frederick V Ramsey; George P Tuszyski; Wenhui Hu
Journal:  Oncotarget       Date:  2015-03-20

7.  Lymphotoxin β receptor activation promotes bladder cancer in a nuclear factor-κB-dependent manner.

Authors:  Mo Shen; Xiuzhi Duan; Ping Zhou; Wu Zhou; Xiuling Wu; Siqi Xu; Yuhua Chen; Zhihua Tao
Journal:  Mol Med Rep       Date:  2014-10-30       Impact factor: 2.952

8.  NF-κB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis.

Authors:  Ae R Noort; Katinka P M van Zoest; Ester M Weijers; Pieter Koolwijk; Chrissta X Maracle; Deborah V Novack; Martin J Siemerink; Reinier O Schlingemann; Paul P Tak; Sander W Tas
Journal:  J Pathol       Date:  2014-08-28       Impact factor: 7.996

9.  Friend or foe: A novel role of β-defensins in tumor development.

Authors:  Johann Röhrl; Edward K Geissler; Thomas Hehlgans
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

10.  TNF Neutralization Results in the Delay of Transplantable Tumor Growth and Reduced MDSC Accumulation.

Authors:  Kamar-Sulu N Atretkhany; Maxim A Nosenko; Violetta S Gogoleva; Ruslan V Zvartsev; Zhihai Qin; Sergei A Nedospasov; Marina S Drutskaya
Journal:  Front Immunol       Date:  2016-04-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.